A SINGLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 18F-FLUORODEOXYGALACTOSE (18F-FDGAL) COMPARED TO 18F-FFLUORODEOXYGLUCOSE (18F-FDG) TO DETECT HEPATOCELLULAR CARCINOMA VIA PET/CT IN PATIENTS WITH CIRRHOSIS OR CHRONIC LIVER DISEASE
- Registry ID
- H16-01905
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Study type
- INTERVENTIONAL
- Sponsor
- BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY
- Last update
- 2017-02-22
Conditions
- CIRRHOSIS OF THE LIVER
- HEPATOCELLULAR CARCINOMA
- LIVER DISEASE
Related clinical trials
- RADIATION THERAPY FOLLOWED BY DURVALUMAB (MEDI4736) AND TREMELIMUMAB AND
SURGERY VERSUS RADIATION THERAPY FOLLOWED BY SURGERY FOR RESECTABLE
HEPATOCELLULAR CARCINOMA. A RANDOMIZED WINDOW OF OPPORTUNITY TRIAL
(DARTS)
- A MULTICENTER, OPEN LABEL, NON-RANDOMIZED FIRST-IN-HUMAN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY,PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF BAY 3547926 ALONE, AND IN COMBINATION, IN PARTICIPANTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
- A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF GSK4532990 FOR STEATOHEPATITIS IN ADULTS WITH ALCOHOL RELATED LIVER DISEASE (ALD)
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE EFFECT OF SELADELPAR ON CLINICAL OUTCOMES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AND COMPENSATED CIRRHOSIS
- A PHASE III DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL TO EVALUATE LIVER-RELATED CLINICAL OUTCOMES AND SAFETY OF ONCE WEEKLY INJECTED SURVODUTIDE IN PARTICIPANTS WITH COMPENSATED NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (NASH/MASH) CIRRHOSIS
- EFFECTS OF NNC0194-0499 ALONE AND IN COMBINATION
WITH SEMAGLUTIDE, OF SEMAGLUTIDE ALONE, AND OF CAGRILINTIDE ALONE AND IN COMBINATION
WITH SEMAGLUTIDE ON LIVER DAMAGE AND ALCOHOL USE IN PEOPLE WITH ALCOHOL-RELATED LIVER
DISEASE
View on source registry